See more : Sutton Harbour Group plc (SUH.L) Income Statement Analysis – Financial Results
Complete financial analysis of Avanos Medical, Inc. (AVNS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avanos Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Sirios Resources Inc. (SIREF) Income Statement Analysis – Financial Results
- AIRA Factoring Public Company Limited (AF.BK) Income Statement Analysis – Financial Results
- Ningbo Donly Co.,Ltd (002164.SZ) Income Statement Analysis – Financial Results
- Midway Holding AB (publ) (MIDW-A.ST) Income Statement Analysis – Financial Results
- Armm Inc. (ARMM) Income Statement Analysis – Financial Results
Avanos Medical, Inc. (AVNS)
About Avanos Medical, Inc.
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.30M | 820.00M | 744.60M | 714.80M | 697.60M | 652.30M | 611.60M | 1.59B | 1.57B | 1.67B | 1.68B | 1.68B | 1.66B |
| Cost of Revenue | 293.60M | 370.00M | 380.30M | 341.50M | 295.40M | 261.40M | 274.70M | 1.03B | 1.04B | 1.12B | 1.07B | 1.08B | 1.07B |
| Gross Profit | 379.70M | 450.00M | 364.30M | 373.30M | 402.20M | 390.90M | 336.90M | 557.90M | 531.60M | 548.60M | 612.20M | 602.50M | 590.80M |
| Gross Profit Ratio | 56.39% | 54.88% | 48.93% | 52.22% | 57.65% | 59.93% | 55.09% | 35.04% | 33.77% | 32.81% | 36.49% | 35.78% | 35.59% |
| Research & Development | 27.20M | 30.60M | 32.30M | 34.90M | 37.70M | 41.80M | 38.20M | 41.10M | 32.30M | 33.60M | 37.90M | 33.00M | 31.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 318.10M | 341.90M | 300.30M | 332.60M | 399.10M | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Other Expenses | 0.00 | 3.50M | 22.80M | 51.90M | 21.10M | 8.20M | 20.10M | 18.30M | 4.50M | -3.80M | -2.40M | -1.50M | -2.80M |
| Operating Expenses | 375.50M | 376.00M | 355.40M | 419.40M | 457.90M | 390.40M | 380.00M | 470.50M | 435.30M | 454.30M | 386.90M | 374.50M | 380.10M |
| Cost & Expenses | 669.10M | 746.00M | 735.70M | 760.90M | 753.30M | 651.80M | 654.70M | 1.50B | 1.48B | 1.58B | 1.45B | 1.46B | 1.45B |
| Interest Income | 2.90M | 1.20M | 200.00K | 1.20M | 6.70M | 7.80M | 2.50M | 600.00K | 300.00K | 2.90M | 2.60M | 2.60M | 4.10M |
| Interest Expense | 15.00M | 10.00M | 3.30M | 15.60M | 15.00M | 26.40M | 31.60M | 32.70M | 33.10M | 6.00M | 100.00K | 800.00K | 200.00K |
| Depreciation & Amortization | 46.10M | 41.10M | 38.30M | 42.90M | 36.90M | 33.50M | 40.00M | 41.00M | 65.40M | 85.40M | 69.20M | 57.60M | 51.10M |
| EBITDA | 50.60M | 77.80M | 8.90M | -2.00M | -12.10M | 65.70M | -600.00K | -65.50M | -76.50M | 179.70M | 297.10M | 288.20M | 265.90M |
| EBITDA Ratio | 7.52% | 14.99% | 6.37% | -0.28% | -1.73% | 6.41% | 3.09% | 9.62% | 10.29% | 10.92% | 17.71% | 17.11% | 16.02% |
| Operating Income | 4.20M | 74.00M | 8.90M | -46.10M | -55.70M | 500.00K | -43.10M | 87.40M | -377.70M | 94.30M | 225.30M | 228.00M | 210.70M |
| Operating Income Ratio | 0.62% | 9.02% | 1.20% | -6.45% | -7.98% | 0.08% | -7.05% | 5.49% | -23.99% | 5.64% | 13.43% | 13.54% | 12.69% |
| Total Other Income/Expenses | -12.10M | -8.80M | 44.80M | -14.40M | -8.30M | -18.60M | -29.10M | -32.10M | -274.80M | -3.10M | 2.50M | 1.80M | 3.90M |
| Income Before Tax | -7.90M | 65.20M | 5.80M | -60.50M | -64.00M | -18.10M | -72.20M | 55.30M | -410.50M | 91.20M | 227.80M | 229.80M | 214.60M |
| Income Before Tax Ratio | -1.17% | 7.95% | 0.78% | -8.46% | -9.17% | -2.77% | -11.81% | 3.47% | -26.07% | 5.45% | 13.58% | 13.65% | 12.93% |
| Income Tax Expense | 2.00M | 14.70M | 600.00K | -33.30M | -18.10M | -9.60M | -40.10M | 15.50M | 15.80M | 64.10M | 73.20M | 77.20M | 72.20M |
| Net Income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M | 57.50M | 79.30M | 39.80M | -426.30M | 27.10M | 154.60M | 152.60M | 142.40M |
| Net Income Ratio | -9.18% | 6.16% | 0.85% | -3.81% | -6.58% | 8.81% | 12.97% | 2.50% | -27.08% | 1.62% | 9.22% | 9.06% | 8.58% |
| EPS | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EPS Diluted | -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| Weighted Avg Shares Out | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M | 47.20M | 46.52M | 46.60M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
| Weighted Avg Shares Out (Dil) | 46.60M | 47.30M | 48.60M | 47.80M | 47.60M | 47.20M | 46.80M | 47.00M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
Avanos: TriVisc Offering Appealing, Strong Growth Across Rest Of Product Portfolio, Revise To Buy
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
Avanos Medical, Inc. to Present at the Stifel 2022 Healthcare Conference
Avanos Medical, Inc. (AVNS) Q3 2022 - Earnings Call Transcript
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
New Strong Sell Stocks for October 5th
New Strong Sell Stocks for September 28th
Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?
Source: https://incomestatements.info
Category: Stock Reports